COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

NCI's CPTAC and PDC Recognized by FedHealthIT for Outstanding Commitment to Excellence and Innovation

This year, the 8th Annual FedHealthIT Innovation Awards recognized programs from the Department of Veterans Affairs, Military Health, Health and Human Services, and Centers for Medicare and Medicaid Services. These programs were carefully selected by their peers for their commitment to excellence,...


CellCarta Will Offer MRM-based Assay Services Using CPTAC Assays Developed at the Fred Hutchinson Cancer Center

In May, a leading provider of precision medicine laboratory services, CellCarta, acquired the commercial rights to the CPTAC-qualified antibody panels and assays developed by the Paulovich laboratory at Fred Hutchinson Cancer Center; they produce high-end multiplex quantitative immuno-MRM mass...


CPTAC Announces New PCC, PGDAC, and PTRC Teams

This month, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, has reaffirmed its commitment to furthering proteogenomics research by announcing the next round of Proteome Characterization Center (PCC; RFA-CA-21...


NCI Welcomes Renewed Commitments to the Cancer Moonshot with Japan and the Republic of Korea

The National Cancer Institute (NCI) of the National Institutes of Health is pleased to announce the renewal of three separate collaborations with Japan and the Republic of Korea (ROK), affirming the two countries’ commitment to international cancer research and care, expanding efforts in the emerging...


Proteogenomic Characterization of In vivo Protein Complexes via Chemical Cross-Linking and Mass Spectrometry

Protein complexes are a fundamental component of physiological and pathological processes. Despite organisms having a limited number of genes and therefore a finite number of proteins at their disposal, the number of possible combinations amongst these proteins is essentially inexhaustible; myriad...


Young Scientist Highlight: Aniket Dagar

The following is the transcript of an interview conducted to highlight promising undergraduate student researcher Aniket Dagar from University of Michigan. Aniket was recently awarded a meritorious poster award for the poster he presented at the 2022 American Association for Cancer Research (AACR)...


CPTAC Glycoproteomic Researchers Develop "Peptide-First" Multi-Attribute Glycan Identification Method

Glycosylation is critical for a wide range of biological processes and is implicated in numerous diseases. Analysis of the glycoproteome has the potential to reveal a wealth of clinical insights, but the heterogeneity of glycosylation makes this analysis difficult. Because of the analytical...


Machine Learning-Derived Metrics Enable Computational Method Comparison in Phosphoproteomics Research

Protein phosphorylation dysregulation has been recognized as a key feature of several diseases, especially cancer. In recent years, phosphoproteomic research has revealed novel, effective biomarkers and drug targets for disease prognosis and treatment. Tandem mass spectrometry (MS/MS)-based...


Proteogenomics Provides New Insights into Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (iCCA) is the second-most common primary liver tumor and has a low 5-year survival rate of 15%. Treatment of iCCA is particularly difficult due to its markedly aggressive progression, late symptom presentation, and early metastasis. In order to improve...


CPTAC Researchers Identify CPT1A as a Potential Therapeutic Target in Platinum-Refractory, High-Grade Serous Ovarian Cancer Patients

At present, typical treatment for patients with high-grade serous ovarian cancer (HGSOC) is surgical debulking coupled with platinum-based chemotherapy. Despite the majority of HGSOCs being sensitive to platinum-based therapy initially, most become resistant over the course of treatment. The...


Pages